• Most Popular
  • Most Shared

UPDATE 1-GlaxoSmithKline gets U.S. Lamictal XR approval

Mon Jun 1, 2009 9:04am EDT

Stocks

   

* Approved as a once-daily add-on epilepsy therapy

Stocks  |  Regulatory News

* Lamictal XR reduces frequency of partial seizures

* Shares flat in moderately rising market (Adds details)

LONDON, June 1 (Reuters) - GlaxoSmithKline (GSK.L), the world's second-largest drugmaker, said on Monday that its Lamictal XR epilepsy drug had been approved in the United States.

Lamictal XR extended release is approved as add-on therapy for adult and adolescent patients who experience partial seizures.

The original version of Lamictal has lost patent protection, pressuring profits, but Glaxo hopes to replace some lost sales with the new tablet.

At 1300 GMT Glaxo shares were flat, underperforming the FTSE 100 .FTSE index which was up 1.2 percent. (Reporting by Ben Deighton, editing by Will Waterman)

Stocks
Regulatory News


More from Reuters

Photo

Honda to recall 440,000 cars globally over airbags

TOKYO (Reuters) - Honda Motor Co said on Wednesday it would recall 437,763 vehicles globally for defective airbags.

» More Top News
A Greek flag at the Bank of Greece is seen near a statue of ancient philosopher Socrates in Athens February 5, 2010. REUTERS/Yiorgos Karahalis

Avoiding "another Greece"

Don't count on the euro zone growing anytime soon. Getting into the single-currency club will be tougher than ever.  Full Article 

Global Markets
An unknown Toyota car covered in preparation for the Chicago Auto Show, February 9, 2010. REUTERS/John Gress
SPECIAL REPORT:

What went wrong at Toyota?

An inside look at the spectacular crisis embroiling one of the world's best-known brands shows a series of unheeded warnings and a stubborn refusal to listen.  Full Article | Video 

Autos